Company: INDP
Filing Date: 2025-06-23
Form Type: DEF 14A
Source: 0001641172-25-016071
Chunk: 12

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-23
Form: DEF 14A
Chunk 12
---
2025.

Stockholders are urged to carefully read
these documents.

Background

On June 12, 2025, we entered into securities
purchase agreements (the “Purchase Agreements”) with certain accredited investors (the “Purchasers”) in the Private
Placement of Notes and Common Warrants. The closing of the Private Placement occurred on June 12, 2025 resulting in gross proceeds of
$2.3 million, before deducting the placement agent’s fees and other offering expenses.

We may continue offering additional Notes and
Common Warrants on the same terms until we have raised a maximum of $5 million in gross proceeds (unless increased at the discretion
of the Company).

The Notes bear interest at the rate of 6% per
year and will mature on July 28, 2026 (the “Maturity Date”). The Notes will convert, together with accrued interest, into
shares of the Company’s common stock (the “Conversion Shares”) on the date (the “Conversion Date”) which
is the earlier of (i) the date that is 30 days from the effectiveness of a reverse split effected by the Company on Nasdaq, and (ii)
the one-year anniversary from the issuance of the Notes. The conversion price per share of common stock (the “Conversion Price”)
will be equal to 80% of the average Nasdaq official closing price of the common stock for the five trading days immediately preceding
and including the Conversion Date, subject to a maximum conversion price of $0.40, as adjusted for stock splits and the like.

If after giving effect to the conversion of the
Notes, any such holder of the Notes would beneficially own in excess of 4.99% or 9.99% of the shares of common stock outstanding immediately
after giving effect to such conversion, then in lieu of receipt of shares of common stock upon conversion, the holder shall receive such
Pre-funded Warrants, in substantially the same form as the Common Warrants, but with an exercise price for the Pre-funded Warrants
of $0.01 per share and no expiration date.

Within 10 days of the later of the Conversion
Date and the date stockholder approval) is obtained, each Purchaser will receive a Common Warrant exercisable for shares of our common
stock in a number equal to (i) 200% of the Conversion Shares if they subscribed on or before the close of business on June 30, 2025 or
(ii) 100